+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
APLLTD

Alembic Pharmaceuticals Share Price

₹845.75 +19.75 (2.39%)
33.02% Gain from 52W Low

18 Sep, 2026 3:59 PM (IST)

Alembic Pharmaceuticals live price: ₹845.75. It opened at ₹828 vs previous close ₹826; intraday high/low: ₹860/₹828. The 50 & 200 DMA stand at ₹814.50/₹811.70.

Alembic Pharmaceuticals Performance

  • Today's Low
  • ₹828
  • Today's High
  • ₹860
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹998
  • Open Price₹828
  • Previous Close₹826
  • Volume677,057
  • 50 DMA₹814.50
  • 100 DMA₹803.20
  • 200 DMA₹811.70

Alembic Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 3.46%
  • Over 3 Month + 10.85%
  • Over 6 Month + 29.03%
  • Over 1 Year -11.81%

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Invest Now

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 24
  • PEG Ratio
  • 1.6
  • Market Cap Cr
  • 16,624
  • P/B Ratio
  • 2.8
  • Average True Range
  • 25.6
  • EPS
  • 35.3
  • Dividend Yield
  • 1.4
  • MACD Signal
  • 2.6
  • RSI
  • 60.71
  • MFI
  • 70.74

Latest Stock News Updates

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed Intimation of One to One Investor Meet.

Alembic Pharmaceuticals Ltd - 533573 - Update On USFDA Inspection Conducted During 3Rd March, 2025 To 7Th March, 2025 At Bioequivalence Facility Located At Vadodara, Gujarat.

Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

The company stated that the USFDA conducted an onsite bioequivalence inspection from August 31 to September 10, 2026

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹845.75
+ 19.75 (2.39%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹821.60
  • 50 Day
  • ₹814.50
  • 100 Day
  • ₹803.20
  • 200 Day
  • ₹811.70

Resistance and Support

844.58 Pivot Speed
  • R3 893.20
  • R2 876.60
  • R1 861.20
  • S1 829.20
  • S2 812.60
  • S3 797.20

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-04 Quarterly Results
2026-05-15 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-04 Quarterly Results & Others To consider other business matters.
2025-08-05 Quarterly Results & Others To consider other business matters.
Date Purpose Remarks
2026-07-29 FINAL Rs.12.00 per share(600%)Final Dividend
2025-07-29 FINAL Rs.11.00 per share(550%)Final Dividend
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)
View Alembic Pharmaceuticals Dividend History Arrow

Alembic Pharmaceuticals Shareholding Pattern

69.87%
10%
8.73%
7.2%
4.17%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. View More
  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • ISIN
  • INE901L01018

Similar Stocks to Alembic Pharmaceuticals

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹845 As on 20 September, 2026 | 12:10

The Market Cap of Alembic Pharmaceuticals is ₹16624.3 Cr As on 20 September, 2026 | 12:10

The P/E ratio of Alembic Pharmaceuticals is 24 As on 20 September, 2026 | 12:10

The PB ratio of Alembic Pharmaceuticals is 2.8 As on 20 September, 2026 | 12:10

The 52 week High & Low of Alembic Pharmaceuticals is ₹998/₹635.8 respectively As on 20 September, 2026 | 12:10

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23